First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

布鲁顿酪氨酸激酶 伊布替尼 慢性淋巴细胞白血病 套细胞淋巴瘤 医学 滤泡性淋巴瘤 华登氏巨球蛋白血症 肿瘤溶解综合征 中性粒细胞减少症 癌症研究 放射免疫疗法 内科学 淋巴瘤 免疫学 白血病 酪氨酸激酶 毒性 化疗 抗体 受体 单克隆抗体
作者
John F. Seymour,Chan Y. Cheah,Ricardo Parrondo,Meghan C. Thompson,Don A. Stevens,Masa Lasica,Michael L. Wang,Abhijeet Kumar,Judith Trotman,Maan Alwan,Wei Ding,Kunthel By,Bilal Tariq,Xiangmei Chen,Shannon Fabre,Jason C. Paik,Amit Kumar Agarwal,Constantine S. Tam
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4401-4401 被引量:7
标识
DOI:10.1182/blood-2023-180109
摘要

Introduction: BTK inhibitors (BTKis) are approved for chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Disease that progresses on BTKis often has BTK mutations that lead to treatment (tx) resistance; novel BTK-targeting agents that overcome BTKi resistance are needed. BGB-16673 is a heterobifunctional small molecule that binds to BTK and E3 ligase, resulting in BTK degradation via ubiquitination. In preclinical models, BGB-16673 degraded wild-type (WT) BTK and known covalent and noncovalent BTKi-resistant mutant proteins, leading to tumor suppression. Methods: Pts with R/R CLL, WM, MCL, MZL, non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or Richter transformation (RT) were eligible for this open-label, first-in-human, phase 1 trial (BGB-16673-101; NCT05006716). Pts must have received ≥2 prior therapies (≥1 for RT) and have an ECOG performance status of 0-2 and adequate end-organ function. In the US and Australia, pts must have received a covalent BTKi (cBTKi) if approved for their disease. BGB-16673 was dosed daily by mouth in 28-day cycles. Escalation using a Bayesian optimal interval design with 6 dose levels (50-600 mg once daily) is planned. Primary objectives are to assess safety/tolerability and establish the maximum tolerated dose (MTD) and recommended phase 2 dose. Key secondary objectives are to assess pharmacokinetics, pharmacodynamics (PD), and preliminary antitumor activity. Safety was assessed according to CTCAE v5.0 (all pts) and iwCLL hematologic toxicity criteria (pts with CLL). Dose-limiting toxicities (DLTs) were assessed in the first 4 weeks. Response was assessed per Lugano criteria for all except CLL (iwCLL 2018 criteria) and WM (iwWM-6 criteria). Results: As of May 26, 2023, 26 pts (10 CLL, 4 MCL, 2 MZL, 4 WM, 4 FL, 1 DLBCL, 1 RT) were enrolled at 5 dose levels (50 mg, 4; 100 mg, 9; 200 mg, 9; 350 mg, 3; 500 mg, 1). Median age was 70.5 y (range, 25-83). Median number of prior therapies was 3.5 (range, 2-9), including cBTKis (n=21; 10 CLL, 4 WM, 4 MCL, 1 MZL, 1 RT, 1 DLBCL), BCL2 inhibitors (n=12; 9 CLL, 2 WM, 1 RT), and noncovalent BTKis (ncBTKis; n=4; 2 CLL, 1 WM, 1 FL). In CLL, del17p/ TP53 mutation (n=8) and unmutated IGHV (n=7) were frequent. Median follow-up was 3.5 mo (range, 0.2-13.9). MTD was not reached. Treatment-emergent AEs (TEAEs) were reported by 88.5% of pts (grade [gr] ≥3, 46.2%; serious, 38.5%). The most common TEAEs were contusion (30.8%; no gr ≥3), pyrexia (23.1%; no gr ≥3), neutropenia/neutrophil count decreased (23.1%; gr ≥3, 15.4%), and lipase increased (23.1%; gr ≥3, 3.8%; all transient and asymptomatic). No hypertension or atrial fibrillation was observed. One pt died from sepsis with possible disease progression. No discontinuations due to AEs occurred. Two pts had dose reductions due to TEAEs (gr 3 hematuria with urinary tract infection and recurrent urothelial carcinoma and gr 2 arthralgia). One DLT occurred in 1 pt at 200 mg (gr 3 maculopapular rash on day 27; after 5-day dose hold, assigned dose was recommenced with persistent gr 1 rash). BGB-16673 exposure increased in a dose-dependent manner. At steady state with doses ≥50 mg daily, BGB-16673 exposure exceeded the calculated half maximal degradation concentration for WT and cysteine 481-mutated BTK for the dosing interval. Preliminary PD data showed deep, sustained reductions in BTK protein levels in peripheral blood and tumor tissue, even at the lowest dose. Most CLL pts experienced lymphocytosis during the first 3 cycles of tx. Twenty of 26 pts (77%) remain on therapy (discontinuation: 4 progressive disease, 2 withdrawal). Of 18 response-evaluable pts, 12 (67%) responded (5/6 CLL, 1/3 MCL, 2/2 MZL, 3/4 WM, 1/2 FL, 0/1 DLBCL; 1 CR in MCL, all others had PR; Figure), including pts who received a cBTKi (n=10) and an ncBTKi (n=2). Responses started at the lowest dose level. All responders remain in response, the longest responder remaining on tx for 60 weeks. Conclusions: Preliminary data from this ongoing, first-in-human study of the novel BTK degrader BGB-16673 demonstrate a tolerable safety profile and clinical responses in heavily pretreated pts with B-cell malignancies, including those with BTKi-resistant disease. Substantial reductions in BTK protein levels in peripheral blood and tumor tissue were also observed, demonstrating proof-of-concept of a strong, on-target effect.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明理萃完成签到 ,获得积分10
刚刚
苏黎世发布了新的文献求助10
刚刚
1秒前
乔安发布了新的文献求助10
1秒前
炫哥IRIS发布了新的文献求助10
1秒前
LaTeXer给积极行天的求助进行了留言
2秒前
ww发布了新的文献求助10
2秒前
Carlo完成签到,获得积分10
3秒前
蓝胖子完成签到 ,获得积分10
4秒前
5秒前
终生科研徒刑完成签到 ,获得积分10
5秒前
6秒前
ysc发布了新的文献求助20
8秒前
9秒前
LKX完成签到 ,获得积分10
9秒前
纯真的诗兰完成签到,获得积分10
10秒前
自然函完成签到 ,获得积分10
10秒前
等一个晴天完成签到,获得积分10
11秒前
as发布了新的文献求助100
11秒前
天天快乐应助科研通管家采纳,获得10
11秒前
研友_VZG7GZ应助科研通管家采纳,获得10
11秒前
个性元枫应助科研通管家采纳,获得10
11秒前
kingwill应助科研通管家采纳,获得20
11秒前
顾矜应助科研通管家采纳,获得10
11秒前
11秒前
慕青应助科研通管家采纳,获得10
11秒前
今后应助科研通管家采纳,获得10
11秒前
隐形曼青应助科研通管家采纳,获得10
11秒前
Hello应助科研通管家采纳,获得10
11秒前
小蘑菇应助科研通管家采纳,获得10
11秒前
Ava应助科研通管家采纳,获得10
12秒前
海东来应助科研通管家采纳,获得30
12秒前
JamesPei应助科研通管家采纳,获得10
12秒前
个性元枫应助科研通管家采纳,获得10
12秒前
茕凡桃七完成签到,获得积分10
12秒前
大个应助科研通管家采纳,获得10
12秒前
所所应助科研通管家采纳,获得10
12秒前
Hello应助科研通管家采纳,获得30
12秒前
12秒前
烟花应助科研通管家采纳,获得10
12秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048